Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GlobeNewswire

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, February 26 at 4:30 p.m. ET

Domestic:	1 833-470-1428
International:	1 646-844-6383
Access Code:	027322

Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section of www.crinetics.com.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations

gdiwakar@crinetics.com

(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications

nbadillo@crinetics.com

(858) 345-6075

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

GlobeNewswire

Crinetics

-5.06%

First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH

SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.

“BALANCE-CAH is designed to evaluate atumelnant for the treatment of CAH in pediatric age patients – for whom the lifelong burden of this disease begins early,” said Dr. Alan Krasner, M.D., Chief Endocrinologist, Crinetics. “For children living with CAH, correcting elevated androgen levels caused by the condition, while preserving the ability to use low glucocorticoid doses for replacement purposes only, is critical in supporting normal growth, development, and metabolic health. By studying atumelnant in this population, we aim to generate insights that could help children live less encumbered by the challenges of this serious endocrine disorder.”

Atumelnant is the first and only small molecule ACTH receptor antagonist in late-stage clinical development and is designed to block the pathway in the adrenal gland that leads to the production of excess androgens associated with classic CAH. The BALANCE-CAH Phase 2/3 study is a potential registrational study of atumelnant in pediatric patients with CAH and will evaluate safety, efficacy, and pharmacokinetics in children and adolescents, a population with significant unmet medical need.

The study will be conducted in three phases. Part A is a Phase 2, open-label, semi-sequential dose-ranging portion of the study. Part B is the Phase 3, double-blind, randomized, placebo controlled confirmatory portion of the study. Part C is an open-label extension portion of the study.

Crinetics recently received Orphan Drug Designation from the U.S. Food & Drug Administration for atumelnant in the treatment of classic CAH.

For more information, visit https://clinicaltrials.gov/study/NCT07159841

About Atumelnant

Investigational atumelnant is the first in class and only once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland in late-stage clinical development. Diseases associated with excess ACTH can have a significant impact on physical and mental health. Novel atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study consistently demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including A4 and 17-hydroxyprogesterone, in a diverse population. Currently in Phase 3 clinical development, atumelnant holds the potential to offer transformational care for individuals living with congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. This breakthrough could revolutionize the management of these conditions, providing hope for unprecedented improvements in quality of life.

About Crinetics Pharmaceuticals

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the Phase 2/3 program for atumelnant for CAH; the plans and timelines for the clinical development of our drug candidates, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of additional research pipeline updates or the expected timing of the advancement of those programs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, data that we report may change following completion or a more comprehensive review of the data related to the clinical studies; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the Company’s product candidates that may limit their development, regulatory approval and/or commercialization; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments or political changes, including the policies related to pricing and pharmaceutical drug reimbursement in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development; Crinetics may use its capital resources sooner than expected or our cash burn rate may accelerate; any future impacts to our business resulting from geopolitical developments outside our control; and the other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Media:

Natalie Badillo

Head of Corporate Communications

nbadillo@crinetics.com

(858) 345-6075

Investors:

Gayathri Diwakar

Head of Investor Relations

gdiwakar@crinetics.com

(858) 345-6340

Risk Warnings and Disclaimers

Add to Favorites

Eli Lilly and Regencell among market cap stock movers on Wednesday

Investing.com

Advanced Micro Devices

-17.31%

Ambarella

+0.86%

Wednesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Eli Lilly and Regencell Bioscience Holdings are rallying, while others like First Solar are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200 billion USD and higher)

Eli Lilly And Co (LLY); Eli Lilly & Co. (LLY) Nears Deal for Ventyx Biosciences (VTYX) - WSJ: +3.59%
Google Inc (GOOGL): +3.18%
Palantir Technologies Inc (PLTR): +2.99%
AbbVie Inc (ABBV): +2.38%
Caterpillar (CAT); Caterpillar CEO Joe Creed to become chairman as Umpleby retires: -3.11%
United Health Group (UNH): -2.41%
Bank Of America (BAC); Wolfe Research downgrades Bank of America stock rating on valuation concerns: -2.47%
JP Morgan Chase (JPM); Wolfe Research downgrades JPMorgan stock rating on expected slower EPS growth: -2.26%
Lam Research Corp (LRCX): -2.26%
Applovin (APP): +3.27%

Large-Cap Stock Movers (Market Cap:$10-$200 billion USD)

Regencell Bioscience Holdings (RGC): +45.47%
Bloom Energy Corp (BE): +7.52%
Intel Corp (INTC); Mobileye to acquire humanoid robotics firm Mentee for $900 million: +6.69%
Invitation Homes Inc (INVH): -7.9%
Vistra Energy Corp (VST): -7.83%
Seagate Technology (STX): -6.95%
Amern Hms 4 (AMH): -5.25%
Western Digital (WDC): -8.9%
First Solar Inc (FSLR): -10.0%
New Providence Acquisition Corp N (ASTS); Scotiabank downgrades AST Spacemobile stock on valuation concerns: -11.54%

Mid-Cap Stock Movers (Market Cap:$2-$10 billion USD)

Crinetics Pharmaceuticals Inc (CRNX); Crinetics Pharmaceuticals prices public offering at $45.95 per share: +13.0%
Compass (COMP); Compass announces proposed $750 million convertible notes offering: +12.79%
CF Acquisition Corp VI (RUMBW): +9.07%
Arrowhead Research Corp (ARWR); Arrowhead Pharmaceuticals plans to offer $700 million in securities: -8.95%
Cleveland Cliffs (CLF); Cleveland-Cliffs stock rating downgraded by KeyBanc on valuation concerns: -9.53%
Qorvo Inc (QRVO): -8.74%
ViaSat (VSAT): -11.38%
Skyworks Solutions Inc (SWKS): -11.64%
Fermi America LLC (FRMI): -11.0%
Ambarella Inc (AMBA): -12.36%

Small-Cap Stock Movers (Market Cap:$300 million - $2 billion USD)

Monte Rosa Therapeutics (GLUE); Monte Rosa’s MRT-8102 shows promising results in reducing inflammation: +49.41%
NovaBay Pharmaceuticals Inc (NBY): +42.22%
Ventyx Biosciences (VTYX); Eli Lilly-Ventyx Deal Could Come Wednesday, Sources Say -- WSJ: +36.67%
Realogy Holdings (HOUS): +20.93%
AXT Inc (AXTI): +19.43%
Neumora Therapeutics (NMRA): +18.76%
GH Research (GHRS): +22.52%
Immuneering (IMRX): +22.17%
ASTX NYSE (ASTX): -3.33%
Summit Semiconductor (DVLT): -17.21%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Eli Lilly and Intel lead market cap stock movers on Wednesday

Investing.com

NovaBay Pharmaceuticals

-18.10%

Alphabet-A

-1.96%

Wednesday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Eli Lilly and Intel are rallying, while others like Western Digital and Hecla Mining are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200B and above)

Eli Lilly And Co (LLY); Eli Lilly & Co. (LLY) Nears Deal for Ventyx Biosciences (VTYX) - WSJ: +3.67%
Google Inc (GOOGL): +1.69%
JP Morgan Chase (JPM); Wolfe Research downgrades JPMorgan stock rating on expected slower EPS growth: -2.8%
Lam Research Corp (LRCX): -2.31%
Facebook Inc (META): -2.28%
Adv Micro Device (: -1.83%
Alibaba-exch (BABA); Freedom Capital Markets downgrades Alibaba stock rating amid rising costs: -2.19%

Large-Cap Stock Movers (Market Cap:$10B-$200B)

Intel Corp (INTC); Mobileye to acquire humanoid robotics firm Mentee for $900 million: +10.89%
Regencell Bioscience Holdings (RGC): +25.79%
First Solar Inc (FSLR): -9.27%
Hecla Mining Comp (HL): -9.5%
Western Digital (WDC): -8.41%
Seagate Technology (STX): -7.64%
New Providence Acquisition Corp N (ASTS); Scotiabank downgrades AST Spacemobile stock on valuation concerns: -5.54%
CoStar Group (CSGP); CoStar Group sets financial targets, announces $1.5 billion buyback: -4.48%

Mid-Cap Stock Movers (Market Cap:$2B-$10B)

Crinetics Pharmaceuticals Inc (CRNX); Crinetics Pharmaceuticals prices public offering at $45.95 per share: +15.66%
Navan Inc (NAVN): +7.53%
Pbf Energy Inc (PBF): +5.62%
Frontline Ltd Ordinary Shares (FRO): +6.9%
Compass (COMP); Compass announces proposed $750 million convertible notes offering: +6.14%
CF Acquisition Corp VI (RUMBW): +9.07%
Skyworks Solutions Inc (SWKS): -10.97%
Arrowhead Research Corp (ARWR); Arrowhead Pharmaceuticals plans to offer $700 million in securities: -6.89%
ViaSat (VSAT): -4.81%
Fermi America LLC (FRMI): -10.16%

Small-Cap Stock Movers (Market Cap:$300M-$2B)

Monte Rosa Therapeutics (GLUE); Monte Rosa to present interim results for NEK7-directed MGD: +54.28%
Ventyx Biosciences (VTYX); Eli Lilly-Ventyx Deal Could Come Wednesday, Sources Say -- WSJ: +37.31%
Neumora Therapeutics (NMRA): +31.87%
NovaBay Pharmaceuticals Inc (NBY): +19.28%
AXT Inc (AXTI): +18.84%
Erasca (ERAS); Piper Sandler initiates Erasca stock with Overweight rating, $5 price target: +16.25%
Immuneering (IMRX): +16.82%
Realogy Holdings (HOUS); Compass announces proposed $750 million convertible notes offering: +13.91%
MBX Biosciences (MBX); UBS initiates coverage on MBX Biosciences stock with Buy rating: +14.91%
ASTX NYSE (ASTX): -0.93%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Crinetics stock ticks lower after announcing $350 million public offering

Investing.com

Advanced Micro Devices

Investing.com -- Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock fell 2.5% in after-hours trading Monday following the company’s announcement of a proposed public offering of $350 million in common stock.

The pharmaceutical company, which focuses on developing therapeutics for endocrine diseases and endocrine-related tumors, also plans to grant underwriters a 30-day option to purchase up to an additional $52.5 million of shares. Crinetics noted that the offering’s completion, size, and terms are not guaranteed.

According to the announcement, Crinetics intends to use the proceeds to fund commercial activities for its PALSONIFY™ launch, research and development of product candidates, and other general corporate purposes. The company may also allocate funds toward potential acquisitions or investments in complementary businesses or technologies.

Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor are serving as joint bookrunning managers for the proposed offering.

Crinetics Pharmaceuticals is headquartered in San Diego and trades on the Nasdaq under the ticker CRNX.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Tesla, Goldman Sachs among market cap stock movers on Monday

Investing.com

Advanced Micro Devices

Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Lam Research and Shopify are rallying, while stocks like AbbVie and Eli Lilly are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200B+ market cap):

Lam Research (LRCX): +5.88%
Shopify (SHOP): +5.3%
Applied Materials (AMAT): +5.54%
Goldman Sachs (GS): +4.83%
Tesla (TSLA): +3.91%
Morgan Stanley (MS): +2.96%
Palantir Technologies (PLTR): +3.68%
Citigroup (C): +3.63%
AbbVie (ABBV): -4.17%
Eli Lilly (LLY): -3.67%

Large-Cap Stock Movers ($10B-$200B market cap):

Regencell Bioscience Holdings (RGC): +23.47%
Apollo-backed (APO) Investor Group Is Said To Invest Over $1bn In Qxo - Bloomberg; Silversun Tech (QXO): +13.69%
AeroVironment (AVAV): +11.65%
AltC Acquisition (OKLO): +13.61%
Kratos Defense (KTOS): +8.24%
Coeur d’Alene Mines (CDE): +7.35%
Okta announces $1 billion share repurchase program; Okta Inc (OKTA): +6.32%
Valero Energy (VLO): +9.65%
Amkor Technology (AMKR): +9.6%
Lumentum Holdings (LITE): -6.42%

Mid-Cap Stock Movers ($2B-$10B market cap):

Vicor Corp (VICR): +22.75%
Nuscale Power (SMR): +14.78%
Crinetics to host conference call on paltusotine and atumelnant data; Crinetics Pharmaceuticals Inc (CRNX): +14.49%
Figure Technology Solutions Ltd (FIGR): +14.08%
Allegro Microsystems Inc (ALGM): +10.18%
Weatherford Intl (WFRD): +11.05%
Barclays upgrades Oscar Health stock rating to Equalweight on balanced risk-reward; Oscar Health (OSCR): +8.75%
Sezzle Inc PK (SEZL): +8.56%
Arrowhead Research Corp (ARWR): -9.97%
Comstock Resources Inc (CRK): -7.51%

Small-Cap Stock Movers ($300M-$2B market cap):

Zenas BioPharma’s obexelimab shows 56% reduction in IgG4-RD flares; Zenas Biopharma (ZBIO): -56.41%
FDA clears GH001 for clinical investigation in the U.S.; GH Research (GHRS): +22.58%
FDA grants breakthrough therapy status to Altimmune’s MASH drug; PharmAthene Inc (ALT): +17.24%
SRM Entertainment (TRON): +17.5%
Sizzle Acquisition (CRML): +15.46%
CONL (CONL): +14.8%
Oxygen Biotherape (TENX): +11.86%
Rayonier Advanced Materials appoints Scott Sutton as new CEO; Rayonier Advanced Materials (RYAM): +19.62%
Kosmos Energy Ltd (KOS): +12.46%
Pieris Pharmaceuticals Inc (PVLA): -12.72%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Crinetics stock soars after strong PALSONIFY launch and positive trial data

Investing.com

Investing.com -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stock surged 19% following the company’s announcement of strong early sales for PALSONIFY and positive clinical trial results for its CAH treatment candidate.

The San Diego-based endocrine disease specialist reported unaudited and preliminary net product revenue exceeding $5 million for PALSONIFY in the fourth quarter of 2025, its first full quarter on the market. The acromegaly treatment, which received FDA approval in September 2025, has garnered over 200 enrollment forms and attracted more than 125 unique prescribers by the end of December.

Simultaneously, Crinetics released positive results from the fourth cohort of its Phase 2 trial for atumelnant, an oral ACTH receptor antagonist being developed for congenital adrenal hyperplasia (CAH). The trial showed that atumelnant (80 mg) achieved a 67% mean reduction in androstenedione levels while allowing 88% of participants who completed 12 weeks of treatment to successfully reduce their glucocorticoid dose to physiologic replacement levels.

"I’m very proud of our team’s strong execution of Palsonify’s launch in acromegaly," said Scott Struthers, founder and CEO of Crinetics. "We are delivering impressive results, highlighted by over 200 enrollment forms in the first three months after FDA approval, a broad prescriber base, and continued momentum toward favorable payer coverage."

The company reported that approximately half of newly filled PALSONIFY prescriptions were reimbursed without requiring bridge supplies, and most prior authorizations have 12-month durations, suggesting favorable payer reception.

Atumelnant’s safety profile remained favorable in the trial, with no serious adverse events, no treatment-related severe adverse events, and notably, no hepatic transaminase adverse events reported among participants.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites